Prolymphocytic Leukemia, Recurrent Mantle Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Richter Syndrome
Conditions
Brief summary
This phase II trial studies how well sotrastaurin acetate works in treating patients with chronic lymphocytic leukemia, small lymphocytic leukemia, prolymphocytic leukemia, or Richter's transformation that has returned or that does not respond to treatment. Sotrastaurin acetate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Detailed description
PRIMARY OBJECTIVES: I. To determine the objective clinical response rate of AEB071 (sotrastaurin acetate) treatment in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL)/prolymphocytic leukemia (PLL)/Richter's transformation (RT). SECONDARY OBJECTIVES: I. To determine the feasibility and tolerability of long-term administration of a fixed dose of AEB071 in patients with relapsed or refractory CLL/SLL/PLL. II. To examine select downstream pharmacodynamic effects in this population of patients after receiving AEB071 including assessment of the wingless-type MMTV integration site family (WNT) signaling pathway. III. To determine the feasibility and tolerability of AEB071 treatment in patients with relapsed or refractory mantle cell lymphoma (MCL) as well as to gain preliminary data regarding efficacy in this patient population. TERTIARY OBJECTIVES: I. Determine the proportion of patients with select germline and somatic deoxyribonucleic acid (DNA) alterations, including in the B-cell receptor (BCR) pathway. II. Determine how mutational and transcriptional status in key genes affects response to this therapy and may have affected response to prior therapies. OUTLINE: Patients receive sotrastaurin acetate orally (PO) twice daily (BID) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 days and then at least every 3 months thereafter.
Interventions
DRUGsotrastaurin acetate
Given PO
OTHERpharmacological study
Correlative studies
OTHERlaboratory biomarker analysis
Correlative studies
Sponsors
Novartis
James Blachly
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 * Life expectancy \>= 2 months * Appropriate histologic diagnosis (a) or (b): * (a) Histologically documented diagnosis of intermediate or high risk CLL/SLL, B-PLL, and RT arising from CLL/SLL according to the 2008 guidelines, meeting criteria for active disease requiring treatment: * Evidence of marrow failure as manifested by the development or worsening of anemia or thrombocytopenia (not attributable to autoimmune hemolytic anemia or thrombocytopenia) * Massive (\>= 6 cm below the costal margin), progressive or symptomatic splenomegaly * Massive nodes (\>= 10 cm) or progressive or symptomatic lymphadenopathy * Autoimmune anemia and/or thrombocytopenia that is poorly responsive to standard therapy * Constitutional symptoms including any of the following: * Unintentional weight loss of 10% or more within 6 mos. * Significant fatigue limiting activity * Fevers \>= 100.5 degrees F for 2 weeks or more without evidence of infection * Night sweats \> 1 month without evidence of infection * Need for cytoreduction prior to stem cell transplantation * (b) Pathologically documented MCL \[defined as either t(11;14) or overexpression of cyclin D1\] for the MCL pilot study * Relapsed after or refractory to at least one prior therapy * Willingness to undergo all study-related evaluations and procedures * Ability to understand and willingness to execute a written informed consent document
Exclusion criteria
* Prior therapy as follows: * Major surgery within 2 weeks * Corticosteroids greater than 20 mg/day prednisone (or equivalent) within 2 weeks unless used by inhalation or topical route, or unless necessary for premedication before iodinated contrast dye, or for autoimmune hemolytic anemia * Cytotoxic chemotherapy or biologic therapy within 4 weeks, excepting BCR kinase inhibitors for which no wash out is required, or * Nitrosoureas within the 6 weeks of the planned first dose of the study drug * Failure to recover toxicity from prior chemo- or radiotherapy to grade 1 * Known active leukemia or lymphoma of the central nervous system (CNS) requiring therapy * Inadequate bone marrow function/hematopoietic reserve, except in the case of documented bone-marrow involvement: absolute neutrophil count (ANC) \< 1 x 10\^9/L * Inadequate bone marrow function/hematopoietic reserve, except in the case of documented bone-marrow involvement: platelets \< 30 x 10\^9/L * Serum total bilirubin \> 2 x ULN (upper limit of normal) * Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 2.5 x ULN, or \> 5 x ULN if CLL/lymphoma is present in the liver * Estimated glomerular filtration rate (GFR) \< 30 mL/min * Patients who are receiving treatment with medications that are known to be strong inducers or inhibitors of cytochrome P450, family 3, subfamily A, polypeptide 4/5 (CYP3A4/5) and CYP3A4/5 substrates with QT prolongation risk that cannot be discontinued prior to study entry * Clinically significant cardiac diseases, including any of the following: * History or presence of ventricular tachyarrhythmia * Presence of unstable/uncontrolled atrial fibrillation (with ventricular rate \> 100 beats per minute \[bpm\]); patients with stable atrial fibrillation are eligible provided that they do not meet any of the other
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of CLL/SLL/PLL/RT patients who achieve an objective clinical response, estimated by the number of complete, partial, or partial responses with lymphocytosis divided by the total number of evaluable patients | Up to 9 months | Categories of response for CLL and PLL patients defined according to criteria published by the International Workshop on CLL. Response for SLL/RT patients will be according to revised response criteria for malignant lymphoma. The objective response rate for all evaluable patients in the phase II study will be calculated with an exact 95% binomial confidence interval (assuming that the number of patients who respond is binomially distributed). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Response duration | From the time at which criteria for CR, PR, or PR with lymphocytosis is first assessed until the date at which recurrent or progressive disease or death due to disease is documented, assessed up to 3 years | For CLL and PLL patients, defined according to the criteria published by the International Workshop on CLL with the modification outlined by Cheson et al. For SLL/RT patients, responses will be according to revised response criteria for malignant lymphoma. Summarized using standard Kaplan-Meier methods. |
| Progression free survival (PFS) | Time from the first dose of the study drug until disease progression or death from any cause, assessed up to 3 years | For CLL and PLL patients, defined according to the criteria published by the International Workshop on CLL with the modification outlined by Cheson et al. For SLL/RT patients, responses will be according to revised response criteria for malignant lymphoma. Summarized using standard Kaplan-Meier methods. |
| Overall survival (OS) | Time from the first dose of the study drug until death, assessed up to 3 years | For CLL and PLL patients, defined according to the criteria published by the International Workshop on CLL with the modification outlined by Cheson et al. For SLL/RT patients, responses will be according to revised response criteria for malignant lymphoma. Summarized using standard Kaplan-Meier methods. |
| Rate of objective clinical response (CR, PR) (optional PLCG2 enriched cohort, if activated) | Up to 3 years | For CLL and PLL patients, defined according to the criteria published by the International Workshop on CLL with the modification outlined by Cheson et al. For SLL/RT patients, responses will be according to revised response criteria for malignant lymphoma. Summarized using standard Kaplan-Meier methods. |
| Response duration (optional PLCG2 enriched cohort, if activated) | From the time at which criteria for CR, PR, or PR with lymphocytosis is first assessed until the date at which recurrent or progressive disease or death due to disease is documented, assessed up to 3 years | For CLL and PLL patients, defined according to the criteria published by the International Workshop on CLL with the modification outlined by Cheson et al. For SLL/RT patients, responses will be according to revised response criteria for malignant lymphoma. Summarized using standard Kaplan-Meier methods. |
| PFS (optional PLCG2 enriched cohort, if activated) | Time from the first dose of the study drug until disease progression or death from any cause, assessed up to 3 years | For CLL and PLL patients, defined according to the criteria published by the International Workshop on CLL with the modification outlined by Cheson et al. For SLL/RT patients, responses will be according to revised response criteria for malignant lymphoma. Summarized using standard Kaplan-Meier methods. |
| OS (optional PLCG2 enriched cohort, if activated) | Time from the first dose of the study drug until death, assessed up to 3 years | For CLL and PLL patients, defined according to the criteria published by the International Workshop on CLL with the modification outlined by Cheson et al. For SLL/RT patients, responses will be according to revised response criteria for malignant lymphoma. Summarized using standard Kaplan-Meier methods. |
| Rate of objective clinical response (CR, PR) (MCL cohort) | Up to 3 years | Responses are defined according the revised response criteria for malignant lymphoma. Summarized using standard Kaplan-Meier methods. |
| OS (MCL cohort) | Time from the first dose of the study drug until death, assessed up to 3 years | Responses are defined according the revised response criteria for malignant lymphoma. Summarized using standard Kaplan-Meier methods. |
| PFS (MCL cohort) | Time from the first dose of the study drug until disease progression or death from any cause, assessed up to 3 years | Responses are defined according the revised response criteria for malignant lymphoma. Summarized using standard Kaplan-Meier methods. |
| Incidence of adverse events (AEs), assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 criteria | Up to 30 days post-treatment | For each disease group, frequency and severity of adverse events will be collected and summarized by descriptive statistics. |
| Frequency of AEs requiring dose reduction or drug discontinuation | Up to 30 days post-treatment | Number of patients who require dose modifications and/or dose delays will be assessed. |
| Number of courses completed | Up to 30 days post-treatment | Number of courses started/completed and the reasons for going off-treatment will be assessed. |
| Pharmacodynamic modulation of the downstream targets of the BCR (including LCP1) after sotrastaurin acetate treatment | Baseline to up to course 1 day 29 | Markers will be summarized univariately in a quantitative manner and also summarized by clinical outcome group graphically to assess potential patterns and relationships. Changes in BCR signaling over time may be evaluated quantitatively using repeated measures models and graphically with individual time plots or box plots. |
| Pharmacodynamic modulation of the downstream targets of nuclear transcription factor kappa-B after sotrastaurin acetate treatment | Baseline to up to course 1 day 29 | Markers will be summarized univariately in a quantitative manner and also summarized by clinical outcome group graphically to assess potential patterns and relationships. |
| Pharmacodynamic modulation of downstream targets of WNT/beta-catenin pathway | Baseline to up to course 1 day 29 | Markers will be summarized univariately in a quantitative manner and also summarized by clinical outcome group graphically to assess potential patterns and relationships. |
| Genomic features associated with response by deep sequencing panel targeted at recurrent mutations in CLL | Up to course 1 day 29 | Markers will be summarized univariately in a quantitative manner and also summarized by clinical outcome group graphically to assess potential patterns and relationships. |
| Response duration (MCL cohort) | From the time at which criteria for CR, PR, or PR with lymphocytosis is first assessed until the date at which recurrent or progressive disease or death due to disease is documented, assessed up to 3 years | Responses are defined according the revised response criteria for malignant lymphoma. Summarized using standard Kaplan-Meier methods. |
Outcome results
None listed